Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.
NCT ID: NCT00801437
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
457 participants
OBSERVATIONAL
2008-10-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
NCT00219596
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
NCT00150267
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
NCT01012245
Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
NCT00143208
Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension
NCT01191008
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Xalacom treatment
patients with primary glaucoma
Xalacom
Xalacom 1 drop into the affected eye daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xalacom
Xalacom 1 drop into the affected eye daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ocular hypertension
* age \>18 years
Exclusion Criteria
* obstructive pulmonary disease
* hypersensitivity to the drug
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Banovce N. Bebravou, , Slovakia
Pfizer Investigational Site
Banská Bystrica, , Slovakia
Pfizer Investigational Site
Bojnice, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Brezno, , Slovakia
Pfizer Investigational Site
Dunajská Streda, , Slovakia
Pfizer Investigational Site
Galanta, , Slovakia
Pfizer Investigational Site
Kežmarok, , Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Pfizer Investigational Site
Krompachy, , Slovakia
Pfizer Investigational Site
Lipany, , Slovakia
Pfizer Investigational Site
Lučenec, , Slovakia
Pfizer Investigational Site
Martin, , Slovakia
Pfizer Investigational Site
Myjava, , Slovakia
Pfizer Investigational Site
Nitra, , Slovakia
Pfizer Investigational Site
Nová Baňa, , Slovakia
Pfizer Investigational Site
Nove Mesto N. Vahom, , Slovakia
Pfizer Investigational Site
Nové Zámky, , Slovakia
Pfizer Investigational Site
Poprad, , Slovakia
Pfizer Investigational Site
Prešov, , Slovakia
Pfizer Investigational Site
Rimavská Sobota, , Slovakia
Pfizer Investigational Site
Rožňava, , Slovakia
Pfizer Investigational Site
Ružomberok, , Slovakia
Pfizer Investigational Site
Sabinov, , Slovakia
Pfizer Investigational Site
Sliač, , Slovakia
Pfizer Investigational Site
Snina, , Slovakia
Pfizer Investigational Site
Spišská Nová Ves, , Slovakia
Pfizer Investigational Site
Stará Ľubovňa, , Slovakia
Pfizer Investigational Site
Stará Turá, , Slovakia
Pfizer Investigational Site
Šaľa, , Slovakia
Pfizer Investigational Site
Topoľčany, , Slovakia
Pfizer Investigational Site
Zlaté Moravce, , Slovakia
Pfizer Investigational Site
Zvolen, , Slovakia
Pfizer Investigational Site
Žiar nad Hronom, , Slovakia
Pfizer Investigational Site
Žilina, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6641053
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.